Melanie Lee PhD, CBE, FMedSci, DSc

Melanie Lee, PhD, CBE, FMedSci, DSc (Hons), became BTG’s Chief Scientific Officer in November 2014 having previously served as a non-Executive Director at the company since November 2010. Melanie previously served as the Chief Executive Officer of NightstaRx Ltd, a Founder and Director of the pharmaceutical consultancy Think10, and a non-executive director of H Lundbeck A/S. Melanie was CEO of Syntaxin Ltd until it was sold to Ipsen, and was the Chair of Cancer Research Technology and a Trustee and Deputy-Chair of Cancer Research UK. During her career Melanie has held a number of positions at Glaxo, GlaxoWellcome, Celltech and UCB. In 2008, Melanie was honoured with a CBE for her services to Medical Science.